Please assess the completion status of the following clinical trial:

Trial Title: Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Maintenance hemodialysis therapy for end-stage renal disease~2. Age 18-85 years~3. ≥ 90 days since dialysis initiation~4. Ability to provide informed consent~5. Pre-dialysis seated systolic blood pressure measurements must be ≥ 120 mm Hg in the 2 weeks before enrollment and on the day of randomization.~Exclusion Criteria~1. Serum potassium ≥6.5 mEq/L within 2 months prior to screening~2. Unscheduled dialysis for hyperkalemia within the 3 months prior to screening~3. Hypotension defined as pre-dialysis SBP \<100 mm Hg (seated measurement) within 4 weeks prior to enrollment~4. Recurrent intra-dialytic hypotension, defined as systolic blood pressure \<80 mm Hg during ≥3 dialysis sessions per 30-day rolling period or treatment for either hypotension or symptoms of hypotension if systolic blood pressure is \< 100 mm Hg during ≥3 dialysis sessions per 30-day rolling period.~5. Mitral valve repair or replacement~6. Severe mitral valve disease by echocardiography, coronary angiography or cardiac magnetic resonance imaging~7. Prior coronary artery bypass graft~8. Anticipated kidney transplant, change to peritoneal dialysis, or transfer to another dialysis unit within 6 months~9. Expected survival \< 6 months~10. Allergy to study medications (ISD, HY, adenosine/diprimidole)~11. Active use of sildenafil, vardenafil or tadalafil~12. History of severe aortic stenosis or other cause of LV outflow obstruction~13. Pregnancy, anticipated pregnancy, or breastfeeding, confirmed by serum pregnancy test on the day of PET scan~14. Incarceration~15. Participation in another intervention study~16. Use of monoamine oxidase inhibitors~17. Contraindication to adenosine including~    * 2nd or 3rd degree heart block, sick sinus syndrome or symptomatic bradycardia (without a functioning pacemaker)~   * moderate or severe asthma~   * chronic obstructive pulmonary disease~18. Active use of any of the study medications unless participant and physician willing to discontinue prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Hydralazine/Isorsorbide Dinitrate (Type: EXPERIMENTAL): Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day
- Placebo (Type: ACTIVE_COMPARATOR): Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.

Based on this trial design, predict the completion outcome and termination type (if applicable).